Literature DB >> 2671010

Antibodies to polyclonal IgA, IgA1, and IgA2 and isotype-specific immune complexes in IgA nephropathy.

C L Jones1, C S Hosking, P Kincaid-Smith, H R Powell, S C Richardson, F H Sennhauser, D M Roberton.   

Abstract

The concentrations of serum IgG and IgM antibodies to polyclonal IgA (IgAp), IgA1, and IgA2 were determined by enzyme immunoassay in 31 patients with IgA nephropathy and 30 healthy controls. Patients with IgA nephropathy had significantly raised concentrations of serum IgA compared to controls (Mann-Whitney U test, P = 0.001) and increased concentrations of conglutinin-binding IgA immune complexes (P = 0.024). No differences in the median concentrations of IgG and IgM anti-IgA antibodies were found between the patients and the controls. In serum samples from healthy controls there was a significant positive correlation between IgM anti-IgAp and IgA immune complex concentrations (P = 0.05), which contrasted with the finding of an inverse correlation between IgM anti-IgAp and IgA immune complex concentrations in patients with IgA nephropathy (P less than 0.05). In addition, the concentrations of conglutinin binding IgM immune complexes in serum were found to correlate with the concentration of IgM anti-IgAp (0.010 less than P less than 0.025), IgM anti-IgA1, and IgM anti-IgA2 (P much less than 0.005 for both) in patients with IgA nephropathy but not in controls. IgM anti-IgA antibodies may be important in augmenting the clearance of IgA immune complexes from the serum of patients with IgA nephropathy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2671010     DOI: 10.1007/bf00918662

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  34 in total

1.  The effect of rheumatoid factor on the clearance of endogenous immune complexes formed in low-affinity mice during the induction of immune complex disease.

Authors:  M E Devey; D N Hogben
Journal:  Int Arch Allergy Appl Immunol       Date:  1987

2.  Anaphylactoid transfusion reactions associated with anti-IgA.

Authors:  G N Vyas; H A Perkins; H H Fudenberg
Journal:  Lancet       Date:  1968-08-10       Impact factor: 79.321

Review 3.  IgA nephropathy: perspectives on pathogenesis and classification.

Authors:  S N Emancipator; G R Gallo; M E Lamm
Journal:  Clin Nephrol       Date:  1985-10       Impact factor: 0.975

4.  In situ immune complex formation in the mouse glomerulus: reactivity with human IgM rheumatoid factor and the effect on subsequent immune complex deposition.

Authors:  P M Ford; I Kosatka
Journal:  Clin Exp Immunol       Date:  1983-02       Impact factor: 4.330

Review 5.  The syndrome of IgA nephropathy.

Authors:  A R Clarkson; A J Woodroffe; K M Bannister; J D Lomax-Smith; I Aarons
Journal:  Clin Nephrol       Date:  1984-01       Impact factor: 0.975

6.  Normal human sera contain antibodies directed at Fab of IgA.

Authors:  S Jackson; R I Montgomery; J Mestecky; C Czerkinsky
Journal:  J Immunol       Date:  1987-04-01       Impact factor: 5.422

7.  Aberrant synthesis of antibodies directed at the Fab fragment of IgA in patients with IgA nephropathies.

Authors:  S Jackson; R I Montgomery; B A Julian; J H Galla; C Czerkinsky
Journal:  Clin Immunol Immunopathol       Date:  1987-11

8.  Rheumatoid factor in rheumatoid arthritis associated renal disease and in lupus nephritis.

Authors:  H Helin; M Korpela; J Mustonen; A Pasternack
Journal:  Ann Rheum Dis       Date:  1986-06       Impact factor: 19.103

9.  Cross-idiotypic specificity among monoclonal IgM proteins with anti- -globulin activity.

Authors:  H G Kunkel; V Agnello; F G Joslin; R J Winchester; J D Capra
Journal:  J Exp Med       Date:  1973-02-01       Impact factor: 14.307

10.  Variable region sequences of murine IgM anti-IgG monoclonal autoantibodies (rheumatoid factors). A structural explanation for the high frequency of IgM anti-IgG B cells.

Authors:  M J Shlomchik; D A Nemazee; V L Sato; J Van Snick; D A Carson; M G Weigert
Journal:  J Exp Med       Date:  1986-08-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.